Compounds > valproic acid
Page last updated: 2024-10-26

valproic acid and Viremia

valproic acid has been researched along with Viremia in 2 studies

Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.

Viremia: The presence of viruses in the blood.

Research Excerpts

ExcerptRelevanceReference
" Given the limited evidence that resting CD4+ T cell infection (RCI) is affected by the histone deacetylase (HDAC) inhibitor valproic acid (VPA), we measured the stability of RCI and residual viremia in patients who added VPA with or without raltegravir (RAL), or enfuvirtide (ENF) with or without VPA, to standard ART."9.14Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. ( Archin, NM; Bosch, RJ; Cheema, M; Coffin, JM; Cohen, M; Eron, J; Margolis, DM; Parker, D; Wiegand, A, 2010)
" Given the limited evidence that resting CD4+ T cell infection (RCI) is affected by the histone deacetylase (HDAC) inhibitor valproic acid (VPA), we measured the stability of RCI and residual viremia in patients who added VPA with or without raltegravir (RAL), or enfuvirtide (ENF) with or without VPA, to standard ART."5.14Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. ( Archin, NM; Bosch, RJ; Cheema, M; Coffin, JM; Cohen, M; Eron, J; Margolis, DM; Parker, D; Wiegand, A, 2010)
"Low-level viremia was quantitated by single copy plasma HIV RNA assay."1.35Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. ( Archin, NM; Bandarenko, N; Bosch, RJ; Coffin, JM; Eron, JJ; Hartmann-Duff, A; Landay, AL; Margolis, DM; Martinson, JA; Palmer, S; Schmitz, JL; Wiegand, A, 2008)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Archin, NM2
Eron, JJ1
Palmer, S1
Hartmann-Duff, A1
Martinson, JA1
Wiegand, A2
Bandarenko, N1
Schmitz, JL1
Bosch, RJ2
Landay, AL1
Coffin, JM2
Margolis, DM2
Cheema, M1
Parker, D1
Eron, J1
Cohen, M1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection[NCT02042248]Phase 16 participants (Actual)Interventional2014-03-31Completed
IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chr[NCT02208167]Phase 16 participants (Actual)Interventional2015-04-07Completed
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]Phase 16 participants (Actual)Interventional2016-03-31Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect[NCT02384395]40 participants (Actual)Interventional2015-09-30Completed
Research In Viral Eradication of HIV Reservoirs[NCT02336074]Phase 260 participants (Actual)Interventional2015-11-27Completed
10493 - MK-0518 Intensification and HDAC Inhibition in Depletion of Resting CD4+ T Cell HIV Infection[NCT00614458]Phase 26 participants (Actual)Interventional2007-04-30Terminated (stopped due to Due to insufficient funds)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Median Change HIV-1 RNA Level Among Participants Completing Week 24 Visit

(NCT02384395)
Timeframe: Baseline, Week 24

Interventioncopies/mL (Median)
DTG/3TC/ABC FDC-590211

Number of Participants With Grade 3 or Higher Adverse Event (AE)

Sign/symptom, lab toxicity, or clinical events, or Grade 3 or higher AE that is definitely, probably, or possibly related to study treatment (NCT02384395)
Timeframe: Baseline through Week 96

InterventionParticipants (Count of Participants)
DTG/3TC/ABC FDC1

Number of Participants With Viral Load Measurement <200 Copies/mL at Week 24

Total number of participants on study at Week 24 with an HIV-1 RNA level less than 200 copies/mL (NCT02384395)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
DTG/3TC/ABC FDC34

Proportion of Treated Participants With HIV-1 RNA to <50 Copies/mL at Week 48

Proportion of participants completing Week 48 with an HIV-1 RNA level less than 50 copies/mL (NCT02384395)
Timeframe: Week 48

Interventionproportion of participants (Number)
DTG/3TC/ABC FDC0.88

Histone H4 Acetylation

Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks

InterventionFold increase pre to post vorinostat (Mean)
Intervention (Arm B - ART + Vaccines + Vorinostat)3.19

Quantitative Viral Outgrowth

Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16

InterventionParticipants with undetectable outgrowth (Number)
Control (Arm A - ART Only)12
Intervention (Arm B - ART + Vaccines + Vorinostat)6

Total HIV DNA From CD4 T-cells

The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18

InterventionHIV-DNA copies/mill CD4+ T cells (log10) (Mean)
Control (Arm A - ART Only)2.95
Intervention (Arm B - ART + Vaccines + Vorinostat)3.06

Viral Inhibition

"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks

InterventionPercentage elimination (Mean)
Control (Arm A - ART Only)-18.25
Intervention (Arm B - ART + Vaccines + Vorinostat)1.50

CD8+ T-cell Responses

Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

,
Intervention% cells CD8+ CD107a+ IFNγ+ (Median)
Post randomisation week 9Post randomisation week 12
Control (Arm A - ART Only)0.0520.062
Intervention (Arm B - ART + Vaccines + Vorinostat)0.1940.263

Percentage of CD4+ CD154+ IFNγ+ T Cells

Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

,
Intervention% cells CD4+ CD154+ IFNγ+ (Median)
Post randomisation week 9Post randomisation week 12
Control (Arm A - ART Only)0.0060.006
Intervention (Arm B - ART + Vaccines + Vorinostat)0.0970.109

A Change in the Number of HIV Infected Cells.

A change in infected cells from prior to the initiation of VPA and MK0518 to after 20 weeks of treatment. (NCT00614458)
Timeframe: 20 weeks

Interventioninfected cells /million cells (Median)
Effect on Latent HIV of Adding Raltegravir and VPA to ART0.390

Trials

1 trial available for valproic acid and Viremia

ArticleYear
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
    PloS one, 2010, Feb-23, Volume: 5, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio

2010

Other Studies

1 other study available for valproic acid and Viremia

ArticleYear
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb

2008